

**Memorial Sloan-Kettering Cancer Center and
Weill Medical College of Cornell University**

Date of preparation: February 8, 2013

A. GENERAL INFORMATION

1. Name: Jan Grimm, MD, PhD
2. Office address: MSKCC, Department of Radiology
1275 York Avenue,
New York, NY 10065, USA

Office Telephone: (646) 888-3095
Office Fax: (646) 888-3059
3. Home address: 475 Main Street, Apt 8F.
New York, NY 10044

Home Telephone: (212) 355-5287
4. Cell phone: (646) 629-5625
5. Pager: (917) 205-0389. 1138 (in house)
6. Email: grimmj@mskcc.org
7. Citizenship: United States of America, Germany
8. Optional Information:
 - a. Date of Birth: 11/28/68
 - b. Place of Birth: Hamburg, Germany
 - c. Race/Ethnicity: Caucasian
 - d. Languages: English, German (both fluent)
 - e. Gender: Male

B. EDUCATIONAL BACKGROUND

Degree	Institution name and location	Dates attended	Year Awarded
MD	University of Hamburg Hamburg, Germany	10/1988-11/1995	1996
PhD	University of Schleswig-Holstein Kiel, Germany	07/1997-12/2001	2005

C. PROFESSIONAL POSITIONS AND EMPLOYMENT

1. Post-doctoral training including residency/fellowship

Title	Institution name and location	Dates held
Intern	University of Hamburg, Germany	12/1995 - 05/1997
Resident	Radiology, University of Kiel, Germany	07/1997 - 12/2001
Research Fellow	Center for Molecular Imaging Research, MGH, Harvard Medical School, Boston, MA	01/2002 - 12/2003
Research Fellow	Molecular Imaging, Dept. of Radiology, MSKCC, New York, NY	07/2006 – 06/2009
Clinical Fellow	Body Imaging, Dept. of Radiology, MSKCC, New York, NY	10/2006 - 12/2007
Resident	Nuclear Medicine, Dept. of Radiology, MSKCC, New York, NY	01/2007 - 06/2009

2. Academic Positions

Title	Institution name and location	Dates held
Instructor	Dept. of Radiology, MGH, Harvard Medical School, Boston, MA	01/2004 – 06/2006
Assistant Member	Memorial Sloan-Kettering Cancer Center, New York, NY	07/2009 - present
Assistant Professor of Radiology	Weill Medical College of Cornell University, New York, NY	08/2009 – present

3. Hospital Positions

Assistant Attending	Radiology and Nuclear Medicine, MSKCC, New York, NY	07/2009 - present
Lab Head	Molecular Pharmacology and Chemistry, Sloan-Kettering Institute, New York, NY	07/2009 - present

D. LICENSURE, BOARD CERTIFICATION, MALPRACTICE1. Licensure

a. State	Number	Date of issue	Date of last registration
NY	251939	02/10/09	11/01/12

- b. If no license:
- (1) Do you have a temporary certificate?
 - (2) Have you passed the examination for foreign medical school graduates?
- c. DEA number: FG1774834
- d. NPI number: 1497915094

2. Board Certification

Diagnostic Radiology (Germany)	N.A.	11/01
American Board of Nuclear Medicine	07840	11/09
American Board of Radiology	56510	07/12

3. Malpractice Insurance

Do you have Malpractice Insurance? **Yes**

Name of Provider: **MSK Insurance US, Inc.**

Premiums paid by: (*choose one*)

- a. self b. group (name) **c. Institution (Memorial Sloan-Kettering Cancer Center)**

E. PROFESSIONAL MEMBERSHIPS

Role	Society	Year
Member	European Congress of Radiology (ECR)	1997
Committee, Member	Deutsche Röntgengesellschaft (DRG)	1997
Member	World Molecular Imaging Congress	2002
Member	RSNA	2005
Member	SNMMI	2009

F. HONORS AND AWARDS

Name of Award	Year
Research Award, Dept. of Radiology, University of Kiel	2001
Soc. of Molecular Imaging Young Investigator Travel Award	2004

G. HOSPITAL AFFILIATION

1. Primary Hospital Affiliation **Memorial Hospital for Cancer and Allied Diseases**

- e. Other Hospital Affiliations: None
- f. Other Institutional Affiliations: None

H. EMPLOYMENT STATUS

1. Name of Current Employer(s): **Memorial Sloan-Kettering Cancer Center**
2. Employment Status (*choose one*): **Full-time**

Full-time salaried by Cornell

- i. **Full-time salaried at Cornell-affiliated hospital**
- ii. Part-time salaried at Cornell
- iii. Part-time salaried at Cornell-affiliated hospital
- iv. Voluntary (self-employed or member of a P.C.)
- v. Other salaried
- vi. Other non-salaried

I. CURRENT AND PAST RESPONSIBILITIES AND PERCENT EFFORT

<u>Activity</u>	<u>Current Percent Effort (%)</u>	<u>Does the activity involve WMC students or researchers? (Y/N)</u>	<u>Does the activity involve MSK trainees or researchers? (Y/N)</u>
Teaching:	0%	No	No
Clinical care:	20%,	Yes (residents)	Yes
Administrative:	0%	No	No
Research:	80%	Yes (Collaboration)	Yes
TOTAL:	100%		MSKCC

J. RESEARCH SUPPORT**Current Research Support:**

<u>Source</u>	<u>Grant #</u>	<u>Total Direct Costs:</u>	<u>Funding Years</u>
14-A427 Starr Cancer Consortium (Grimm)		\$600,000	08/01/10-07/31/13
<u>Title:</u> <i>Molecular Imaging to assess tumor-associated macrophages with targeted nanoparticles</i>			
The goal of this study is to target tumor-associated macrophages (TAM) with nanoparticles for PET imaging to be able to assess noninvasively TAM in cancer patients.			
Role: Principal Investigator, 3.96 cal			
		\$50,000	01/01/13-12/31/13
Experimental Therapeutics Center, intramural (Grimm)			
<u>Title:</u> <i>Clinically approved nanoparticles as environmental-responsive self reporting drug delivery system.</i>			

Role: Principal Investigator, 1.8 cal

GC219226 \$50,000 07/01/12-06/30/14

Nanotechnology Center Fund (Grimm)

Title: *A liposomal nanosensor to interrogate immediate radiation therapy response.*

This application utilizes a unique sensor nanoparticle for MR imaging (developed in Grimm Lab) to interrogate a novel biological effector in radiation therapy (obtained from Kolesnick Lab) in an approach that allows immediate assessment of radiosensitivity of tumors by MRI.

Role: Principal Investigator, 1.2 cal

GC218482 \$ 60,000 03/01/12 - 02/28/14

Society of Nuclear Medicine (Thorek)

Title: *Multimodal, high resolution and dynamic imaging of sentinel and distal metastatic lymph nodes using intra-lymphatic 18F-FDG mapping.*

The proposed work has translational applicability as it investigates a novel use of an FDA approved agent.

Role: Mentor; this award supports a two-year research endeavor that promotes integration of molecular imaging into the career of the trainee.

\$100,000 01/01/13-12/31/14

The Imaging and Radiation Sciences Program (IMRAS)

Title: *Monitoring single dose radiation therapy with a smart MRI sensor*

This application utilizes a novel smart imaging agent to interrogate a novel biological effector in radiation therapy.

Role: Principal Investigator, 1.2 cal

PC111667 \$225,000 09/30/12-09/29/15

Congressionally Directed Medical Research Programs

Department of Defense

Title: *Prognosticating nanoparticles for molecular imaging of prostate cancer.*

In this application, we present as a solution to this problem a theranostic nanoparticle that is able to (i) distinguish indolent from aggressive PC with PET imaging; (ii) monitor therapy and (iii) specifically deliver a drug. We will (iv) utilize PSMA biology to prime the tumor for subsequently improved therapy.

Role: Principal Investigator, 0.84 cal

R01 EB014944-01 \$1,250,000 04/01/12-01/31/16

NIBIB

Title: *Cerenkov-emission based nanosensors to detect biologic activities in vivo.*

The goal is to utilize clinically applicable gold and iron oxide nanoparticles to modulate Cerenkov signal and to create switchable molecular imaging agents based upon radioactivity.

Role: Principal Investigator, 3.0 cal

Completed Research Support:

Research Grant	German Research Foundation	Euro 130,000	2002-2003
RSNA Seed Grant	RSNA	USD 30,000	2005
Pelican Fellowship	Pelican Cancer Foundation	USD 7,500	2007-2008

K. EXTRAMURAL PROFESSIONAL RESPONSIBILITIES

Activity	Name	Date
Assoc. Editor	JK Nuclear Medicine	2012-present
Assoc. Editor/Reviewer	Molecular Imaging	2007-present
Reviewer	Clinical Cancer Research	2009-present
Reviewer	Cancer Research	2009-present
Reviewer	Investigative Radiology	2009-present
Reviewer	Biomaterials	2009-present
Reviewer	J Biomedical Imaging	2009-present
Reviewer	Future Drugs Circulation	2009-present
Reviewer	J Biological Chemistry	2009-present
Reviewer	PNAS	2010-present
Reviewer	PLOS	2010-present

INVITED LECTURES

1. October 28, 2013 Hangtsou, China
2. September 5, 2013 Stanford University; Stanford, California
3. June 8, 2013 *Cerenkov Imaging & Cerenkov imaging: Promises and Challenges*, Society of Nuclear Medicine; Vancouver, BC, Canada
4. April 9, 2013 *Activatable theranostic systems*, American Chemical Society (ACS); Savannah, Georgia
5. February 22, 2013 *Faster than the Speed of Light*, University of Central Florida; Orlando, Florida
6. September 5, 2012 *Cerenkov Imaging*, World Molecular Imaging Congress; Dublin, Ireland
7. December 16, 2011 *Faster than the Speed of Light*, Mount Sinai; New York, NY
8. August 30, 2011 *Cerenkov luminescence imaging for the use of PET tracers in the intraoperative setting*, 19th International Symposium on Radiopharmaceutical Sciences; Amsterdam, The Netherlands
9. July 1-3, 2010 *Molecular Imaging in Breast Cancer*, Annual meeting of the German society for Senology; Hamburg, Germany
10. June 21-24, 2010 *Nanoparticles in MR imaging*, Nanotech Conference; Anaheim, CA
11. May 12-15, 2010 *Activatable imaging agents*, Annual meeting of the German Roentgen Society; Berlin, Germany
12. April 26-30, 2010 *Enzymatically activatable Imaging Agents*, German Research Society

- Excellence-Academy; Aachen, Germany
13. Jan. 27-Feb. 2, 2010 *MR imaging with nanoparticles*, SNM Midwinter meeting; Albuquerque, New Mexico
 14. 2009 *Molecular Imaging – basic science tool or future of clinical imaging*, Tr@m Seminar, MSKCC; New York, NY
 15. May 2009 *Molecular Imaging in Prostate Cancer*, German Cancer Foundation - Symposium on Novel tools for risk assessment and early detection of premalignant lesions and cancer; Bonn, Germany
 16. 2009 *PET/CT – current and future clinical applications*, European Society of Radiology (ESR); Vienna, Austria
 17. 2008 *Molecular Imaging – Gate to the future*, 2nd Pelican Prostate Colloquium; Basingstoke, UK
 18. 2007 *Molecular Imaging in cancer research and beyond*, 27th Blankenese Conferences; Hamburg-Blankenese, Germany
 19. July 1-2, 2006 *Trends in Molecular Imaging*, Workshop Molekulare Bildgebung; Jena, Germany
 20. 2005 *Introduction to Molecular Imaging*, Workshop at the 85th meeting of the German Röntgengesellschaft; Wiesbaden, Germany
 21. 2004 *Molekulare Bildgebung mit MRT*, Workshop at the 85th meeting of the German Röntgengesellschaft; Wiesbaden, Germany
 22. 2003 *Molekulare Bildgebung mit MRT*, 20th MR Symposium, Technische Universität München; München, Germany
 23. 2003 *Molecular Imaging with MRI and superparamagnetic nanoparticles*, Workshop at the 84th meeting of the German Röntgengesellschaft; Wiesbaden, Germany
 24. February 13, 2003 *New Horizons in Molecular Imaging*, Symposium on Cancer and Photonics; Heidelberg, Germany

Recent Session Chairs

- 2007: ECR in Vienna, WMI in Nice (also organizer of the session and scientific committee member)
 2012 Program Chair Molecular Imaging, SNMMI
 2012: Poster Chair, World Molecular Imaging Society
 2013 Program Chair Molecular Imaging, SNMMI
 2013: Poster Chair, World Molecular Imaging Society

K. BIBLIOGRAPHY

a. Peer reviewed articles

(Grimm J shared first authorship)*

1. **Grimm J**, Zeller W, Zander AR. “Separation and characterization of mobilized and unmobilized peripheral blood progenitor cells by counterflow centrifugal elutriation.” *Exp Hematol* **1995**, 23(6): 535-44.
2. Krueger W, Stockschrader M, Sobottka I, Betker R, De Wit M, Kroger N, **Grimm J**, Arland M, Fiedler W, Erttmann R, Zander AR. “Antimycotic therapy with liposomal amphotericin-B for

- patients undergoing bone marrow or peripheral blood stem cell transplantation.” *Leuk Lymphoma* **1997**, 24(5-6): 491-9.
3. **Grimm J**, Zeller W, Zander AR. “Soluble interleukin-2 receptor serum levels after allogeneic bone marrow transplantations as a marker for GVHD.” *Bone Marrow Transplant* **1998**, 21(1): 29-32.
 4. Stockschlader M, Hassan HT, Krog C, Kruger W, Loliger C, Horstman M, Altnoder M, Clausen J, **Grimm J**, Kabisch H, Zander A. “Long-term follow-up of leukemia patients after related cryopreserved allogeneic bone marrow transplantation.” *Br J Haematol* **1997**, 96(2): 382-6.
 5. Zander AR, Berger C, Kroger N, Stockschlader M, Kruger W, Horstmann M, **Grimm J**, Zeller W, Kabisch H, Erttmann R, Schonrock P, Kuse R, Braumann D, Illiger HJ, Fiedler W, de Witt M, Hossfeld KD, Weh HJ. “High dose chemotherapy with busulfan, cyclophosphamide, and etoposide as conditioning regimen for allogeneic bone marrow transplantation for patients with acute myeloid leukemia in first complete remission.” *Clin Cancer Res* **1997**, 3(12 Pt 2): 2671-5.
 6. Muller-Hulsbeck S, **Grimm J**, Suwelack D, Heller M. “Mechanical assistance for enhancement of in vitro effectiveness for hydrodynamic thrombectomy.” *Invest Radiol* **1999**, 34(11): 669-77.
 7. Muller-Hulsbeck S, Bathe M, **Grimm J**, Heller M. “Enhancement of in vitro effectiveness for hydrodynamic thrombectomy devices. Simultaneous high-pressure rt-PA application.” *Invest Radiol* **1999**, 34(8): 536-42.
 8. Muller-Hulsbeck S, Schwarzenberg H, Tschach T, **Grimm J**, Heller M. “[In vitro comparison of a size 6F and 8F high-speed rotational catheter for mechanical thrombus fragmentation].” *Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr* **1999**, 170(1): 94-8.
 9. Todriia TV, Drize NI, Chertkov IL, **Grimm J**, Zander A. “[Telomerase activity in the mouse bone marrow and subpopulations of spleen colony-forming units].” *Biull Eksp Biol Med* **1999**, 127(3): 311-3.
 10. **Grimm J**, Karger N, Lusse S, Winoto-Morbach S, Krisch B, Muller-Hulsbeck S, Heller M. “Characterization of ultrasmall magnetite [correction of paramagnetic magnetite] particles as superparamagnetic contrast agents in MRI.” *Invest Radiol* **2000**, 35(9): 553-6.
 11. Jahnke T, Brossmann J, Voshage G, Hilbert C, Muller-Hulsbeck S, **Grimm J**, Toellner D, Heller M. “[Mid-term follow-up after placement of the new balloon-expandable VIP-stent into the iliac arteries].” *Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr* **2000**, 172(4): 381-5.
 12. Karger N, Biederer J, Lusse S, **Grimm J**, Steffens J, Heller M, Gluer C. “Quantitation of renal perfusion using arterial spin labeling with FAIR- UFLARE.” *Magn Reson Imaging* **2000**; 18(6): 641-7.
 13. Müller-Hulsbeck S, **Grimm J**, Jahnke T, Brossmann J, Hilbert C, Heller M. “[First results after implantation of the new balloon-expanded Bridge- Stent into the iliac artery].” *Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr* **2000**, 172(10): 836- 41.
 14. Burklein D, Lochmuller E, Kuhn V, **Grimm J**, Barkmann R, Muller R, Eckstein F. “Correlation of thoracic and lumbar vertebral failure loads with in situ vs. ex situ dual energy X-ray absorptiometry.” *J Biomech* **2001**, 34(5): 579-87.
 15. **Grimm J**, Mueller-Huelsbeck S, Mueller M, Egbers HJ, Brinkmann G, Heller M. “Evaluation of hydroxyapatite implants in vertebral bodies and extremities by contrast-enhanced magnetic resonance imaging.” *Arch Orthop Trauma Surg* **2001**, 121(3): 158-61.
 16. **Grimm J**, Muller-Hulsbeck S, Jahnke T, Hilbert C, Brossmann J, Heller M. “Randomized study to compare PTA alone versus PTA with Palmaz stent placement for femoropopliteal lesions.” *J Vasc Interv Radiol* **2001**, 12(8): 935-42.
 17. **Grimm J**, Muller-Hulsbeck S, Heller M. “Comparison of the mechanical thrombectomy efficacy of

- the Amplatz thrombectomy device and the Cragg thrombolytic brush in vitro.” *Invest Radiol* **2001**, 36(4): 204-9.
18. **Grimm J**, Muller-Hulsbeck S, Blume J, Biederer J, Heller M. “[Comparison of biphasic spiral CT and MnDPDP-enhanced MRI in the detection and characterization of liver lesions].” *Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr* **2001**, 173(3): 266-72.
 19. Jahnke T, Link J, Muller-Hulsbeck S, **Grimm J**, Heller M, Brossman J. “Treatment of infrapopliteal occlusive disease by high-speed rotational atherectomy: initial and mid-term results.” *J Vasc Interv Radiol* **2001**, 12(2): 221-6.
 20. Muhle C, Brossmann J, Biederer J, **Grimm J**, Mohr A, Heller M. “[Value of kinematic MRI in the evaluation of patients with exacerbated pain in cervical spine motion compared with static MRI].” *Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr* **2001**, 173(2): 126-32.
 21. Muller-Hulsbeck S, **Grimm J**, Leidt J, Jahnke T, Heller M. “Comparison of in vitro effectiveness of mechanical thrombectomy devices.” *J Vasc Interv Radiol* **2001**, 12(10): 1185-91.
 22. Müller-Hülsbeck S, Brossmann J, Jahnke T, **Grimm J**, Reuter M, Bewig B, Heller M. “Mechanical thrombectomy of major and massive pulmonary embolism with use of the amplatz thrombectomy device.” *Invest Radiol* **2001**, 36(6): 317-22.
 23. Müller-Hülsbeck S, **Grimm J**, Jahnke T, Häselbarth G, Heller M. “Flow patterns from metallic vascular endoprostheses: in vivo results.” *Eur Radiol* **2001**, 11: 893-901.
 24. Priebe M, Paulsen F, Jahnke T, **Grimm J**, Heller M, Muller-Hulsbeck S. “[Mechanical brush-catheter abrasion method for the isolation and culture of human umbilical vein endothelial cells. First in vitro results].” *Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr* **2001**, 173(10): 955- 8.
 25. Biederer J, Busse I, **Grimm J**, Reuter M, Muhle C, Freitag S, Heller M. “[Sensitivity of MRI in detecting alveolar infiltrates: Experimental studies].” *Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr* **2002**, 174(8): 1033-9.
 26. Biederer J, Reuter M, Both M, Muhle C, **Grimm J**, Graessner J, Heller M. “Analysis of artefacts and detail resolution of lung MRI with breath-hold T1-weighted gradient-echo and T2-weighted fast spin-echo sequences with respiratory triggering.” *Eur Radiol* **2002**, 12(2): 378-84.
 27. Jahnke T, Voshage G, Muller-Hulsbeck S, **Grimm J**, Heller M, Brossmann J. “Endovascular Placement of Self-expanding Nitinol Coil Stents for the Treatment of Femoropopliteal Obstructive Disease.” *J Vasc Interv Radiol* **2002**, 13(3): 257-66.
 28. Muhle C, Brossmann J, Biederer J, Jahnke T, **Grimm J**, Heller M. “[Alar ligaments: radiological aspects in the diagnosis of patients with whiplash injuries].” *Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr* **2002**, 174(4): 416-22.
 29. Muller-Hulsbeck S, Jahnke T, **Grimm J**, Behm C, Hilbert C, Frahm C, Biederer J, Brossmann J, Heller M. “[Early results with a monorail-stent-balloon device for endovascular treatment of renal artery stenosis].” *Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr* **2002**, 174(3): 335- 41.
 30. Muller-Hulsbeck S, Walluscheck KP, Priebe M, **Grimm J**, Cremer J, Heller M. “Experience on endothelial cell adhesion on vascular stents and stent-grafts: first in vitro results.” *Invest Radiol* **2002**, 37(6): 314-20.
 31. Muller-Hulsbeck S, Jahnke T, Liess C, Glass C, Paulsen F, **Grimm J**, Heller M. “In vitro comparison of four cerebral protection filters for preventing human plaque embolization during carotid interventions.” *J Endovasc Ther* **2002**, 9(6): 793-802.
 32. Muller-Hulsbeck S, **Grimm J**, Liess C, Hedderich J, Bergmeyer M, Heller M. “Comparison and modification of two cerebral protection devices used for carotid angioplasty: in vitro experiment.” *Radiology* **2002**, 225(1): 289-94.

33. Muller-Hulsbeck S, **Grimm J**, Leidt J, Heller M. "In vitro effectiveness of mechanical thrombectomy devices for large vessel diameter and low-pressure fluid dynamic applications." *J Vasc Interv Radiol* **2002**, 13(8): 831-9.
34. Oudkerk M, Torres CG, Song B, Konig M, **Grimm J**, Fernandez-Cuadrado J, Op de Beeck B, Marquardt M, van Dijk P, de Groot JC. "Characterization of liver lesions with mangafodipir trisodium-enhanced MR imaging: multicenter study comparing MR and dual-phase spiral CT." *Radiology* **2002**, 223(2): 517-24.
35. Both M, Jahnke T, Reinhold-Keller E, Reuter M, **Grimm J**, Biederer J, Brossmann J, Gross WL, Heller M, Mueller-Huelsbeck S. "Percutaneous management of occlusive arterial disease associated with vasculitis: a single center experience." *Cardiovasc Intervent Radiol* **2003**, 26(1): 19-26.
36. **Grimm J**, Jahnke T, Muhle C, Heller M, Muller-Hulsbeck S. "Influence of Thrombus Age on the Mechanical Thrombectomy Efficacy of the Amplatz Thrombectomy Device In Vitro." *Cardiovasc Intervent Radiol* **2003**, 26(2): 265-8.
37. **Grimm J**, Brunn H, Heller M, Mueller-Huelsbeck S. "Hemolytic effect of deformed intra-arterial stents and stent grafts in vitro." *Eur Radiol* **2003**, 13(6): 1333-8.
38. Mohr A, Priebe M, Taouli B, **Grimm J**, Heller M, Brossmann J. "Selective water excitation for faster MR imaging of articular cartilage defects: initial clinical results." *Eur Radiol* **2003**, 13(4): 686-9.
39. Muller-Hulsbeck S, Jahnke T, Liess C, Glass C, **Grimm J**, Heller M. "Comparison of various cerebral protection devices used for carotid artery stent placement: an in vitro experiment." *J Vasc Interv Radiol* **2003**, 14(5): 613-20.
40. Muller-Hulsbeck S, Dimitte DN, Jahnke T, Hedderich J, **Grimm J**, Heller M. "[In-vitro comparison of the effectiveness of different high-speed rotatory catheters]." *Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr* **2003**, 175(3): 406-12.
41. **Grimm J**, Potthast A, Wunder A, Moore A. "Magnetic resonance imaging of the pancreas and pancreatic tumors in a mouse orthotopic model of human Cancer." *Int J Cancer* **2003**, 106: 806-11.
42. Moore A, **Grimm J**, B Han, P Santamaria. "Tracking the recruitment of diabetogenic CD8+ T-cells to the pancreas in real time." *Diabetes* **2004**, 53(6): 1459-1466.
43. **Grimm J**, Perez M, Josephson L, Weissleder R. "Novel nanosensors for rapid detection of telomerase activity." *Cancer Research* **2004**, 64: 639-643.
44. **Grimm J***, Kirsch D, Windsor SD, Bender Kim CF, Santiago PM, Ntziachristos V, Jacks T, Weissleder R. "Use of Gene Expression Profiling to Direct In Vivo Molecular Imaging of Lung Cancer." *Proc Nat Acad Science* **2005**, 102(40): 14404-14409.
45. Zacharakis G, Kambara H, Shih H, Ripoll J, **Grimm J**, Saeki Y, Weissleder R, Ntziachristos V. "Volumetric tomography of fluorescent proteins through small animals in-vivo." *Proc Nat Acad Science* **2005**, 102 (51): 18252-18257.
46. Kim CF, Jackson EL, Kirsch DG, **Grimm J**, Shaw AT, Lane K, Kissil J, Olive KP, Sweet-Cordero A, Weissleder R, Jacks T. "Mouse models of human non-small-cell lung cancer: raising the bar." *Cold Spring Harb Symp Quant Biol* **2005**, 70:241-250.
47. Rabin O, Perez JM, **Grimm J**, Wojtkiewicz G, Weissleder R. "An x-ray CT imaging agent based on long-circulating bismuth sulfide nanoparticles." *Nature Materials* **2006**, 5: 118.
48. Tannos B, **Grimm J***, Perry JF, Chen JW, Weissleder R, Breakfield S. "Metabolic biotinylation of cell surface receptors for in vivo imaging." *Nature Methods* **2006**, 3(5):391-6.
49. Campanella GS, **Grimm J**, Manice LA, Colvin RA, Medoff BD, Wojtkiewicz GR, Weissleder R, Luster AD. "Oligomerization of CXCL10 Is Necessary for Endothelial Cell Presentation and In

- Vivo Activity.” *J Immunol.* **2006**, Nov 15; 177 (10):6991-8.
50. Ventura A, Kirsch DG, McLaughlin ME, Tuveson DA, **Grimm J**, Lintault L, Newman J, Reczek EE, Weissleder R, Jacks T. “Restoration of p53 function leads to tumor regression in vivo.” *Nature* **2007**, 445: 661-665.
 51. Kirsch DG, Dinulescu DM, Miller JB, **Grimm J**, Santiago PM, Young NP, Nielsen GP, Quade BJ, Chaber CJ, Schultz CP, Takeuchi O, Bronson RT, Crowley D, Korsmeyer SJ, Yoon SS, Hornicek FJ, Weissleder R, Jacks T. “A Spatially- and Temporally-Restricted Mouse Model of Soft Tissue Sarcoma.” *Nature Medicine* **2007**, 13(8):992-7.
 52. Pittet MJ, **Grimm J***, Berger C, Tamura T, Wojtkiewicz G, Nahrendorf M, Romero P, Swirski FK, Weissleder R. “In vivo imaging of T-cell delivery to tumors after adoptive transfer.” *Proc Nat Acad Science* **2007**, 104 (30): 1257-61.
 53. Kircher M, **Grimm J**, Swirski FK, Libby P, Gerszten RE, Allport JR, Weissleder R (2008) “Noninvasive in vivo imaging of monocyte trafficking to atherosclerotic lesions.” *Circulation* **2008**, Jan 22;117(3):388-95.
 54. Perez JM, **Grimm J***, Lee Josephson, Ralph Weissleder. “Integrated nanosensors to determine levels and functional activity of human telomerase.” *Neoplasia* **2008**, 10(10):1066-72.
 55. Santra S, Kaittanis C, **Grimm J**, Perez JM. “Drug/dye-loaded, multifunctional iron oxide nanoparticles for combined targeted cancer therapy and dual optical/magnetic resonance imaging.” *Small* **2009**, 5(16): 1862-8.
 56. Kirsch DG, **Grimm J**, Guimares AR, Wojtkiewicz GR, Perez BA, Santiago PM, Anthony NK, Forbes T, Dopke K, Weissleder R, Jacks T. “Imaging primary lung cancers in mice to study radiation biology.” *Int J Radiat Oncol Biol Phys.* **2010** Mar 15;76(4): 973-977. PMID: PMC2847457.
 57. Ruggiero A, Holland JP, Lewis JS, **Grimm J** (2010) Cerenkov luminescence imaging of medical isotopes. *J Nuclear Med* 51(7):1123-30.
 58. Holland, JP, Normand, G, Ruggiero, A, Lewis, JS and **Grimm, J** (2011). “Intraoperative imaging of PET radiotracers using Cerenkov luminescence emissions.” *Molecular Imaging* 10(3): 177. PMID: PMC3083828
 59. Thorek DL, Abou DS, Beattie BJ, Bartlett RM, Huang R, Zanzonico PB, **Grimm J** (2012). “Positron lymphography: multimodal, high-resolution, dynamic mapping and resection of lymph nodes after intradermal injection of 18F-FDG. *J Nucl Med Sep*; 53(9):1438-45. PMID: PMC3537831
 60. Santra S, Jativa SD, Kaittanis C, Normand G, **Grimm J**, Perez JM (2012). “Gadolinium-Encapsulating Iron Oxide Nanoprobe as Activatable NMR/MRI Contrast Agent.” *ACS Nano.* 2012 Aug 28; 6(8):7281-94. Epub 2012 Jul 18. PMID: PMC3429787
 61. Thorek DLJ, Ogirala A, Beattie BJ, **Grimm J** (2013). “Quantitative imaging of disease signatures through radioactive decay signal conversion.” *Nature Medicine* (19):1345-50
 62. Thorek DLJ, Ogirala A, Beattie BJ, **Grimm J** (2013). Quantitative imaging of disease signatures through radioactive decay signal conversion. *Nature Medicine* (19) 1345-1350
 63. Thorek DJ, Riedl C, Grimm J (2013) Clinical Cerenkov luminescence imaging of 18F-FDG. *JNM* (in press).

b. Reviews and Editorials

1. Wunder A, **Grimm J**, Müller-Ladner U. “Molekulare Bildgebung bei rheumatoider Arthritis

- [Molecular Imaging in rheumatoid arthritis].” *Z Rheumatol* **2003**, 62 (Suppl 2) II/1-II/4.
2. Hengerer A, Wunder A, Wagenaar D, Vija AH, Shah M, **Grimm J**. “From Genomics to clinical Molecular Imaging.” *Proceeding of the IEEE* **2005**, 93 (4): 1-10.
 3. **Grimm J**, and Wunder A. “Molekulare Bildgebung: Stand der Forschung [Current state of molecular imaging research].” *Röfo Fortschr Geb Röntgenstr Neuen Bildgeb Verfahr* **2005**, 177: 326-337.
 4. **Grimm J**, Kircher M, Weisslerer R. “Cell tracking. Principles and Applications.” *Radiology* **2007**, 47(1): 25-33.
 5. **Grimm J**, Hricak H. “Imaging in Urology – looking forward.” *Curr Opin Urol.* **2008** Jan, 18(1):61-4.
 6. **Grimm J**, Scheinberg D. “Will nanotechnology influence targeted cancer therapy.” *Semin Radiat Oncol.* 2011 Apr; 21(2):80-7.
 7. Henneweer C, **Grimm J**. “Clinical applications in Molecular Imaging. Pediatric Radiology” *Pediatr Radiol.* 2011 Feb; 41(2):199-207. Epub 2010 Dec 3.
 8. Thorek D, **Grimm J**. “Enzymatically activatable imaging probes.” *Curr Pharm Biotechnol.* 2012 Mar; 13(4):523-36.

c. Book chapters

1. Zander A, Zeller W, Stockschläder M, Berger C, Krüger W, **Grimm J**, Hummel K, Lölliger C, Kühnl P, Kabisch H. Mobilization of progenitor cells for autologous and allogeneic transplantation. In: Gene Technology. In: Zander AR, Ostertag W, Afanaiev BV, Grosveld F, editors. Stem Cell and Leukemia Research. NATO ASI Series Vol h 94. Berlin: Springer-Verlag; 1996; p 531-6.
2. **Grimm J**, Heller M. Radiologische Schnittbilddiagnostik in der Onkologie [Imaging diagnostics in oncology]. In: Bruhn HD, Fölsch UR, Kneba M, Löffler H, editors. *Onkologische Therapie*. Stuttgart: Schattauer-Verlag 2004; chpt. 2.
3. **Grimm J**, Hengerer A, Schultz CP, Wunder A. Molecular Imaging. In: Oppelt A (ed.) *Imaging systems for medical diagnostics*. Publicis MCD Verlag, Erlangen 2005; chpt. 19.
4. **Grimm J**. Combination of SPECT and CT. In: Ntziachristos V (ed) "Textbook of in-vivo imaging in vertebrates". Willey & Sons, London 2007; chpt 8.2.
5. Schoder H, **Grimm J**, Larson S. Metabolic Imaging. In: DeVita, Hellman and Rosenberg (eds) *Cancer: Principles & Practice of Oncology* (8th ed). Lippincot Williams & Wilkins 2008; chpt 4.6.

d. Abstracts

Not individually listed, over 60 abstracts between 1999 and 2008

e. Thesis

1. **Grimm J** (1996) Counterflow Centrifugal Elutriation (CCE) von Knochenmark, Stammzellseparations- und Leukaphereseprodukten zur T-Zell-Depletion sowie zur Anreicherung und Charakterisierung CD34-positiver Zellen [dissertation]. Germany: Universität Hamburg, MD-Thesis (Dr. med)
2. **Grimm J** (2006) Molecular imaging with magnetic resonance imaging and iron oxide particles: novel opportunities for radiology. University of Kiel, PhD Thesis (Habilitation)

Date: 10/08/2013

Signature:

A handwritten signature in cursive script, appearing to read "Jan Grimm". The signature is written in black ink on a white background.